胸腺肽α-1辅助吸入糖皮质激素/长效β_(2)受体激动剂对哮喘-慢性阻塞性肺疾病重叠综合征的疗效  

Therapeutic effect of thymosinα-1 assisted inhaled corticosteroid/long-actingβ_(2) agonist treatment on asthma-chronic obstructive pulmonary syndrome overlap syndrome

作　　者：周敬奎 曹娟 张娜[1] ZHOU Jingkui;CAO Juan;ZHANG Na(Department of Respiratory and Critical Care Medicine,the Second Affiliated Hospital of Luohe Medical College,Luohe 462000,China;Department of Respiratory and Critical Care Medicine,Luohe Central Hospital,Luohe 462000,China)

机构地区：[1]漯河医学高等专科学校第二附属医院呼吸与危重症医学科,漯河462000 [2]漯河市中心医院呼吸与危重症医学科,漯河462000

出　　处：《西北药学杂志》2024年第2期144-148,共5页Northwest Pharmaceutical Journal

基　　金：河南省医学科技攻关计划项目(编号:LHCJ20200890)。

摘　　要：目的观察胸腺肽α-1辅助吸入糖皮质激素(inhale corticosteroids,ICS)/长效β_(2)受体激动剂(long actiongβ_(2)-agonist,LABA)治疗对哮喘-慢性阻塞性肺疾病重叠综合征(asthma-chronic obstructive pulmonary disease overlap syndrome,ACOS)患者肺功能和免疫功能的影响。方法选取75例ACOS患者,用随机数字表法分为对照组(ICS/LABA治疗)和辅助治疗组(胸腺肽α-1辅助ICS/LABA治疗),比较2组治疗前后急性加重次数、慢性阻塞性肺疾病自我评估(COPD assessment test,CAT)评分、哮喘控制测试(asthma control test,ACT)评分、肺功能[第1秒用力呼气容积(forced expirotovy volume in one second,FEV_(1))、FEV_(1)/用力肺活量(forced vital capacity,FVC)值和呼气峰流速(peak expiratory flow,PEF)]、免疫功能(CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)值)、疗效及不良反应发生情况。结果辅助治疗组的总有效率(97.37%)显著高于对照组(78.38%),P<0.05;辅助治疗组急性加重次数、CAT评分明显低于对照组(P<0.05),ACT评分明显高于对照组(P<0.05);辅助治疗组FEV_(1)、FEV_(1)/FVC值及PEF明显高于对照组(P<0.05);辅助治疗组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)值均显著高于对照组(P<0.05);2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论胸腺肽α-1辅助ICS/LABA治疗ACOS可有效提高患者的免疫功能,促进肺功能恢复,且安全性好。Objective To observe the effect of thymosinα-1 assisted inhaled corticosteroid(ICS)/long-actingβ_(2) agonist(LABA)treatment on pulmonary function and immune function in patients with asthma-chronic obstructive pulmonary syndrome(COPD)overlap syndrome(ACOS).Methods A total of 75 patients with ACOS were divided into control group(ICS/LABA treatment)and adjuvant treatment group(thymosinα-1 assisted ICS/LABA treatment)by random number table method.The number of acute exacerbations,COPD assessment test(CAT)scores,Asthma Control Test(ACT)scores,pulmonary function[forced expiratory volume in one second(FEV_(1)),FEV_(1)/forced vital capacity(FVC)and peak expiratory flow(PEF)],immune function(CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)),therapeutic effect,and adverse reactions were compared between the 2 groups.Results The total effective rate in the auxiliary treatment group(97.37%)was significantly higher than that in the control group(78.38%)(P<0.05).The number of acute exacerbations and CAT score in the auxiliary treatment group were significantly lower than those in the control group(P<0.05),and ACT score was significantly higher than that in the control group(P<0.05).FEV_(1),FEV_(1)/FVC and PEF in the auxiliary treatment group were significantly higher than those in the control group(P<0.05).CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the auxiliary treatment group were significantly higher than those in the control group(P<0.05).There was no statistically significant difference in the total incidence rate of adverse reactions between the 2 groups(P>0.05).Conclusion Thymosinα-assisted ICS/LABA treatment for ACOS can effectively improve the patients’immune function and promote the recovery of pulmonary function,with good safety.

关 键 词：胸腺肽Α-1 糖皮质激素 长效β_(2)受体激动剂 哮喘-慢性阻塞性肺疾病重叠综合征 肺功能 免疫功能 

分 类 号：R979.5[医药卫生—药品]